Reduced combination of genetic variants to predict and stratify alzheimer's disease

The Defense Health Agency awarded a $396,000 Project Grant to the Vlaams Instituut Voor Biotechnologie - Flanders Institute For Biotechnology (VIB), a non-profit biomedical research institute in Belgium, under the Military Medical Research and Development (CFDA 12.420) program. The grant, with a performance period from September 1, 2024 to August 31, 2027, supports VIB's research project focused on "Reduced Combination of Genetic Variants to Predict and Stratify Alzheimer's Disease." VIB has a track record of conducting cutting-edge life sciences and biotechnology research, including through previous federal grants from agencies like the National Institutes of Health, National Cancer Institute, and Department of the Army. The CFDA 12.420 program funds a range of biomedical research initiatives to improve health outcomes for military service members, veterans, and the general public. VIB has also participated as a sub-awardee on larger NIH program projects, such as the Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) program led by the Mayo Clinic.